Loading...

PRQR

PRQR

PROQR THERAPEUTICS NV

(PRQR)

2025 6-K

Investor Event Announcement

25 Mar '26

2025 Results Announced

12 Mar '26

Board Changes Announced

9 Feb '26

ProQR Updates

8 Jan '26

Quarterly Results

6 Nov '25

Analyst Event Summary

3 Nov '25

Regulatory Update

20 Oct '25

Q2 Financial Results

7 Aug '25

Clinical Trial Announcement

26 Jun '25

Annual Meeting Results

3 Jun '25

First Quarter Results

8 May '25

Shareholder Meeting Announc...

1 May '25

Leadership Appointments

14 Apr '25

Annual Financial Results

13 Mar '25

Filing Amendment

12 Dec '24

Investor Event Update

11 Dec '24

Funding Announcement

11 Dec '24

Management Change

10 Dec '24

Investor Event Announcement

5 Dec '24

Q3 2024 Results

7 Nov '24

Equity Offering

25 Oct '24

Quarterly Results

8 Aug '24

Annual Meeting Results

22 May '24

Financial Results Report

9 May '24

New Program Data

8 May '24

Board Nomination Notice

23 Apr '24

Axiomer IP Defense

19 Apr '24

Year End Results

13 Mar '24

Patent Upheld

15 Feb '24

New Data Release

19 Jan '24

New Collaboration

5 Jan '24

External Links:

SEC

On June 26, 2025, ProQR Therapeutics N.V. announced the submission of a Clinical Trial Application (CTA) for a Phase 1 study of AX-0810, which targets NTCP. This event is positive for investors as it indicates advancement in drug development.

AI Assistant

PROQR THERAPEUTICS NV

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.